Clinical-pathological review of 14 cases of merkel cell carcinoma

2002 ◽  
Vol 10 (5) ◽  
pp. 196-202 ◽  
Author(s):  
Adel Quttainah ◽  
Achilles Thoma ◽  
Samih Salama
Keyword(s):  
Cell Carcinoma ◽  
Wide Local Excision ◽  
Primary Tumour ◽  
Primary Treatment ◽  
Merkel Cell ◽  
Disease Free Interval ◽  
Free Interval ◽  
Stage Ia ◽  
Disease Free

Merkel cell carcinoma (MCC) is a rare, primary, cutaneous, neuroendocrine skin tumour that occurs commonly in the head, neck or extremities of elderly white people. Fourteen cases of MCC in the Hamilton Regional Cancer Centre between 1992 and 2000 have been reviewed. Seven cases required a panel of immunohistochemical markers and two cases required electron microscopy for confirmation. Seven men and seven women were treated, and ranged from 67 to 96 years of age (mean 77.7 years). The primary tumour was located in the head and neck in seven patients (50%), in the extremities in four patients (29%) and on the trunk in two patients (14%). One patient had an unknown primary tumour location. Ten patients had stage Ia disease at presentation, three had stage Ib disease, and one presented with stage II disease. Primary treatment consisted of wide local excision in nine patients, wide local excision and radiotherapy in four patients and radiotherapy only in one patient. Seven patients had recurrence, five were disease free up to their most recent follow-up, one died of unrelated causes, and one was lost to follow-up after primary treatment. Of the seven patients with recurrence, two had local recurrence, two had lymph node recurrence and three developed metastases. Disease-free intervals were 69% and 50% for six-month and one-year follow-up, respectively. No difference in outcome was observed between stage Ia and Ib disease. The patient with stage II disease at presentation developed metastases. Longer duration of disease before presentation had a higher incidence of recurrence with distant metastases. Extremity lesions had the best prognosis associated with disease-free interval. Early management with excision and radiotherapy improved the disease-free interval.

Expression of A9 Antigen and Loss of Blood Group Antigens as Determinants of Survival in Patients with Head and Neck Squamous Carcinoma

1987 ◽  
Vol 96 (3) ◽  
pp. 221-230 ◽  
Author(s):  
Thomas E. Carey ◽  
Gregory T. Wolf ◽  
S. Hsu ◽  
J. Poore ◽  
K. Peterson ◽  
...  
Keyword(s):  
Head And Neck ◽  
Blood Group ◽  
Squamous Cell ◽  
Primary Tumor ◽  
Primary Tumor Site ◽  
Disease Free Interval ◽  
Free Interval ◽  
Disease Free

The murine monoclonal antibody (A9), raised to the human squamous cell carcinoma (SCC) cell-line UM-SCC-1, defines a squamous cell antigen associated with aggressive biologic behavior of SCC cell lines in vivo and in vitro. In the present investigation, A9 antigen was detected in tissue sections from 37 consecutive, previously untreated patients with SCC of the head and nack. All tumors were positive for A9 binding, although three distinct patterns (reflecting different intensities of A9 expression) were identified. The intensity of A9 expression was independent of primary tumor site, tumor differentiation, keratinization, or growth pattern. The frequency of high expression (Pattern 1) grew with increasing T class, N class, and tumor stage, and was associated with loss of blood group expression in the tumor and with low levels of lymphocyte infiltration In the tumor. Strong A9 expression had a statistically signification association with low nuclear grade (i.e., tumors with more mature and fewer enlarged nuclei, P = 0.019), low vascular/stromal response (i.e., patchy response rather than continuous, P = 0.014), and impaired in vitro lymphokine production by peripheral blood leukocytes ( P = 0.0011). Of greatest interest, however, was the strong association of high A9 expression with shortened disease-free interval (DFI) ( P = 0.085) and survival ( P = 0.081) relative to patients with weak A9 tumor staining (Patterns 2 and 3). Similarly, the loss of blood group antigen expression was strongly associated with decreased DFI ( P = 0.038) and survival ( P = 0.062). While neither Pattern 1 A 9 expression nor loss of blood group reach statistical significance in prediction of survival, the combination of Pattern 1 A 9 expression and loss of blood group expression in primary tumors was significantly associated, both with decreased disease-free interval ( P = 0.017) and with decreased overall survival ( P = 0.011) (median length of follow-up = 22 months). The length of follow-up (LFU) ranged from 2 to 38 months, with a median LFU of 22 months. While the number of patients (37) is small, the significant association between the expression of these cell-surface markers with relapse and survival indicates that immunohistologic staining of the primary tumor will be an important prognostic indicator useful in identification of individual patients at greatest risk of recurrence or early death from head and neck cancer, independent of tumor size, site, or stage at presentation. These markers may thus provide means of selecting patients who should receive adjuvant therapy and more intensive monitoring for the early detection of recurrent disease.

Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up

1985 ◽  
Vol 6 (2) ◽  
pp. 123-130 ◽  
Author(s):  
J. M. M. Raemaekers ◽  
L. V. A. M. Beex ◽  
A. J. M. Koenders ◽  
G. F. F. M. Pieters ◽  
A. G. H. Smals ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Tumor Tissue ◽  
Disease Free Interval ◽  
Free Interval ◽  
Estrogen Receptor Activity ◽  
Long Term Follow Up ◽  
Disease Free

The POSCH trial: 13 year follow-up and disease-free interval analysis

1994 ◽  
Vol 109 (1-2) ◽  
pp. 354
Author(s):  
H. Buchwald ◽  
C.T. Campos ◽  
J.R. Boen ◽  
P. Nyugen ◽  
S.E. Williams
Keyword(s):  
Interval Analysis ◽  
Disease Free Interval ◽  
Free Interval ◽  
Disease Free

Prognostic significance of disease-free interval in head and neck cutaneous squamous cell carcinoma with nodal metastases

Head & Neck ◽  
2012 ◽  
Vol 35 (8) ◽  
pp. 1138-1143 ◽  
Author(s):  
Ardalan Ebrahimi ◽  
Jonathan R. Clark ◽  
Nazanin Ahmadi ◽  
Carsten E. Palme ◽  
Gary J. Morgan ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Prognostic Significance ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Nodal Metastases ◽  
Disease Free Interval ◽  
Free Interval ◽  
Disease Free

scholarly journals Medularni karcinom stitaste zlezde-uticaj postoperativne transkutane zracne terapije u lokalnoj kontroli i rezultatima lecenja

2003 ◽  
Vol 50 (3) ◽  
pp. 125-130
Author(s):  
Vesna Stankovic ◽  
Nenad Borojevic ◽  
Radan Dzodic ◽  
Ivana Golubicic
Keyword(s):  
Thyroid Gland ◽  
Randomized Study ◽  
Time Interval ◽  
Treatment Results ◽  
Disease Free Interval ◽  
Total Survival ◽  
Free Interval ◽  
Total Therapy ◽  
Disease Free

In the period of Octo. 01, 1987. up to Dec. 31, 1998. retrospective-prospective, non-randomized study was conducted at IORS, which included 36 patients diagnosed with thyroid gland medullar cancer. Our study had the following aims: evaluation of treatment results following probability of total survival, survival without signs of disease and disease-free interval until local reccurrence of the disease and influence of parameters of transcutaneous radiotherapy (intensity of total tumor dose and length of disease-free interval from date of performed operation to beginning of radiotherapy). After finished treatment, median of the patient follow-up was 37,75 months (3,5 up to 141 monts); probability of total five-year survival was 62,61% and of 10 year survival was 23,48%. Probability of 5-year survival, without signs of disease was 37,13%, and of 10-year survival 18,56%. As to radiotherapy parameters, intensity of total therapy dose was statisticaly insignificant, while time interval to beginning of transcutaneuos radiotherapy, shorter than 2 months, was statistically significant in relation to prognosis of disease outcome.

Our experience in the surgical treatment of renal carcinoma metastases

1996 ◽  
Vol 63 (4) ◽  
pp. 476-478
Author(s):  
A. Cozzoli ◽  
G. Cancarini ◽  
S. Cosciani Cunico
Keyword(s):  
Renal Cell Carcinoma ◽  
Surgical Treatment ◽  
Renal Carcinoma ◽  
Disease Free Interval ◽  
Free Interval ◽  
Synchronous Metastases ◽  
Disease Free ◽  
Metachronous Metastases ◽  
Unfavourable Prognostic Factor

The authors report their experience in the surgical treatment of synchronous and metachronous metastases from renal cell carcinoma. From January 1986 to December 1992, 47 nephrectomised patients (11.6%) out of 403 underwent contemporary or subsequent metastasectomy. Metastases were synchronous in 18 cases (38.3%), while metachronous metastases appeared in 29 (61.7%) after a mean disease-free interval of 28 months. After a mean follow-up of 36 months, out of the 18 cases with synchronous metastases, 9 died, 4 are in progression and 5 are still alive and NED; of the 29 patients with metachronous metastases, 3 died, 6 are in progression and 20 are still alive and NED. In conclusion, while the presence of synchronous metastases is an unfavourable prognostic factor even after their removal, results after surgery of metachronous metastases are encouraging.

scholarly journals Melanoma ganglionic metastasis 30 years after treatment of the primary tumor: a case report

1996 ◽  
Vol 114 (2) ◽  
pp. 1131-1133
Author(s):  
Alfio José Tincani ◽  
Antonio Santos Martins ◽  
Henriette de Toledo Lage ◽  
Lincoln Santos Souza
Keyword(s):  
Case Report ◽  
Primary Tumor ◽  
Primary Treatment ◽  
Disease Free Interval ◽  
Free Interval ◽  
Number Of Factors ◽  
Disease Free

The recurrence of melanoma in patients is well-documented, and is dependent on a number of factors. We report a case in which a patient had a case of ganglionar metastasis in the neck after a 30-year disease-free interval following primary treatment.

Merkel Cell Carcinoma of the Head and Neck

2021 ◽  
pp. 229255032110319
Author(s):  
Frances-Claire Eichorn ◽  
Arbind Dubey ◽  
Kumar Alok Pathak
Keyword(s):  
Cell Carcinoma ◽  
Head And Neck ◽  
Merkel Cell Carcinoma ◽  
Stage I ◽  
Stage Iii ◽  
Treatment Modalities ◽  
Merkel Cell ◽  
Disease Free ◽  
Disease Specific

Merkel cell carcinoma (MCC) of the head and neck is a rare and aggressive non-melanoma skin cancer. The objective of this study was to assess the oncological outcome of MCC by retrospective review of electronic and paper records of a population-based cohort of 17 consecutive cases of the head and neck MCC without distant metastasis, diagnosed in Manitoba between 2004 and 2016. The average age of the patients at initial presentation was 74.1 ± 14.4 years with 6 patients presenting with stage I, 4 with stage II, and 7 with stage III disease. Both surgery or radiotherapy alone were the primary treatment modalities in 4 patients each and the remaining 9 patients had a combination of surgery with adjuvant radiotherapy. During the median follow-up of 52 months, 8 patients had recurrent/residual disease and 7 eventually died of it ( P = .001). Metastatic spread of disease to the regional lymph nodes was observed in 11 patients either at presentation or during the follow-up and to the distant sites in 3 patients. At the time of the last contact on November 30, 2020, 4 patients were alive and disease-free, 7 had died of disease, and 6 had died of other causes. The case fatality rate was 41.2%. Five-year disease-free and disease-specific survivals were 51.8% and 59.7%, respectively. The 5-year disease-specific survival was 75% for early stage MCC (stage I and II) and 35.7% for stage III MCC. Early diagnosis and intervention are crucial for disease control and improving survival.

Sign in / Sign up

Export Citation Format

Share Document